Table 2. Characteristics in 27 patients with recurrent GBM who underwent cytoreductive surgery.
| Pre-BEV group | BEV group | P value | |
|---|---|---|---|
| Patient No | 9 | 18 | |
| Age (median) | 67 y | 61 y | 0.33 |
| Preoperative KPS (median) | 80% | 80% | 0.37 |
| Laterality (left/right) | 6 cases/3 cases | 6 cases/12 cases | 0.10 |
| Tumor location | 0.54 | ||
| Frontal | 1 case | 3 cases | |
| Temporal | 3 cases | 7 cases | |
| Parietal | 4 cases | 8 cases | |
| Occipital | 1 case | 0 case | |
| Duration from primary surgery to recurrence (median) | 16.9 months | 22.0 months | 0.11a |
| Recurrent tumor volume (mean) | 8.93 mL | 16.3 mL | 0.25 |
| Extent of resection (mean) | 92.9% | 93.3% | 0.96 |
| BCNU wafer implantation | 1 case (11%) | 12 cases (67%) | |
| Postoperative KPS (median) | 70% | 80% | 0.39 |
| KPS change after surgery (stable/decrease) | 5 cases/4 cases | 10 cases/8 cases | 1.00 |
| Postoperative Bevacizumab | – | 8 cases (53%) | |
| IDH mutation status (mut/wild) | 1 case/8 cases | 1 case/17 cases | 0.51 |
aP values were calculated by Log-rank test
BEV: bevacizumab, GBM: glioblastoma multiforme, IDH: isocitrate dehydrogenase, KPS: Karnofsky Performance Status.